RESEARCH PEPTIDE FUNDAMENTALS / QUESTIONS
Frequently Asked Questions
Each answer names the study design behind it, because the design is usually the part of the answer that is missing elsewhere.
What does retatrutide do?
In published trials, retatrutide reduces body weight, blood glucose and liver fat. The largest published effect comes from a 48-week randomised, double-blind, placebo-controlled phase 2 obesity trial in 338 adults, which reported a mean body-weight change of -24.2 percent at the 12 mg dose against -2.1 percent on placebo [4]. A phase 2 trial in 281 adults with type 2 diabetes reported an HbA1c reduction of 2.02 percent at 24 weeks against 0.01 percent on placebo, and a body-weight reduction of 16.94 percent at 36 weeks [5]. A phase 2a substudy in 98 participants with metabolic dysfunction-associated steatotic liver disease reported a relative liver-fat reduction of 82.4 percent at the 12 mg dose [3]. All three are surrogate measurements rather than clinical events, and retatrutide is investigational and not approved anywhere.
How does retatrutide work?
Retatrutide is a single 39-amino-acid molecule that agonises three receptors simultaneously — GLP-1, GIP and glucagon. The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin secretion, while controlled glucagon-receptor activation adds energy expenditure and lipid mobilisation. Cryo-electron microscopy has resolved the molecule bound to all three receptors and reported it as approximately 8.9-fold more potent than native GIP at the GIP receptor, but 0.3-fold and 0.4-fold relative to the endogenous hormones at the glucagon and GLP-1 receptors respectively [2]. That structural work establishes what the molecule does at the level of the protein. It is not clinical evidence, and mechanism never substitutes for outcome.
How to reconstitute retatrutide?
This site does not publish preparation, reconstitution or administration instructions for any compound, and nothing here is a protocol. Retatrutide is an investigational drug that has been studied only under clinical-trial conditions, where preparation and administration were handled by trial pharmacy staff under a protocol that is not public in operational detail. The formulation facts that do appear in the literature are pharmacological rather than procedural: retatrutide is acylated with a C20 fatty diacid so that it binds albumin, and the first-in-human phase 1b trial measured an elimination half-life of approximately six days, which is what made the once-weekly subcutaneous schedule used in trials feasible [6]. Material sold outside a trial through research channels has no verified identity, concentration, purity or sterility, so no preparation instruction could be reliable even in principle.
Is retatrutide FDA approved?
No. Retatrutide is investigational and has not been approved by the Food and Drug Administration or by any other regulator as of 2026; it remains in phase 3 trials [1]. This is a meaningful distinction for anyone appraising the literature rather than a formality. An approved drug arrives with a regulator-reviewed label, a public summary of the evidence the regulator found persuasive, and a mandatory adverse-event reporting channel. An investigational compound has none of those, and its entire public record is the set of trials its sponsor has chosen to publish. Everything currently readable about retatrutide sits below the confirmatory rung of the development ladder.
What does BPC-157 do in the body?
In animals, BPC-157 accelerates tissue repair, and the mechanism most consistently linked to that effect is angiogenesis. A 2017 study reported that it up-regulates the VEGFR2 receptor and promotes its internalisation with downstream VEGFR2, Akt and endothelial nitric oxide synthase signalling, demonstrated in a chick chorioallantoic membrane assay, a rat hindlimb ischaemia model and cultured human vascular endothelial cells [11]. Earlier foundational work in Wistar rats reported reduced gastric ulcer area with an ulcer-formation inhibition ratio of 45.7 to 65.6 percent at higher doses [12]. What BPC-157 does in a human body is, in the strict sense, unknown: a 2025 narrative review states that only three pilot studies have examined it in humans and that rigorous large-scale trials are lacking [9].
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a human gastric juice protein. Human growth hormone is a 191-amino-acid protein produced by the pituitary gland, and the two are unrelated in structure, origin and regulation. The likely source of the confusion is that one proposed mechanism for BPC-157 involves sensitisation of the growth hormone receptor in cultured tendon fibroblasts, which is a downstream signalling observation in a cell system rather than a statement that the peptide is a growth hormone or raises growth hormone levels. Common online claims that BPC-157 causes weight loss, builds muscle or raises testosterone are not supported by the published evidence.
Does BPC-157 work immediately?
There is no human efficacy trial of BPC-157 of any duration, so there is no measured onset of effect in people to report. A 2025 review counted three small pilot studies in humans and noted the absence of rigorous large-scale trials [9]. The pharmacokinetic data that do exist are preclinical: a study in rats and beagle dogs reported linear pharmacokinetics with an elimination half-life under 30 minutes and rapid breakdown into small peptide fragments [10]. That figure describes how quickly the peptide clears, which is a different question from how quickly an effect appears or how long one lasts — a short half-life is entirely compatible with a slow biological effect, and the two are frequently conflated. Community reports of rapid improvement are anecdotal, not clinical evidence, and are particularly difficult to interpret because most soft-tissue injuries improve over time regardless of intervention.
Does BPC-157 damage the liver?
No human study has been designed to answer this. The only directly relevant published measurement comes from a first-in-human intravenous safety pilot in two healthy adults, which reported no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [8]. That result is reassuring at the narrowest possible scale and cannot establish hepatic safety: with two participants and no control arm, the study can only exclude effects so common they would appear in nearly everyone exposed, and it covers a single short exposure rather than any period of repeated use. There are no long-term human safety data for BPC-157 of any kind, so the honest statement is that hepatic safety in humans is untested rather than established in either direction.
What is thymosin alpha 1?
Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated polypeptide that the body cleaves from a larger precursor called prothymosin alpha. The N-terminal acetylation is essential to its biological activity. The synthetic version used clinically is sequence-identical and is known generically as thymalfasin. It is classed as a thymic peptide and biological response modifier, and a comprehensive review of four decades of clinical literature describes it as approved as a drug in more than 35 countries and as usually well tolerated, with mild local injection-site reactions the most common adverse effect [14].
What does thymosin alpha 1 do?
It modulates the interface between innate and adaptive immunity. It signals through Toll-like receptors, notably TLR2 and TLR9, on dendritic cells and monocytes, promoting their maturation, interleukin-12 production and antigen presentation, which drives T-cell maturation and a Th1-polarised response; in parallel it can engage the indoleamine 2,3-dioxygenase pathway to generate regulatory T cells. Measurable immunological effects have been reported in patients: a retrospective review of 76 patients with severe COVID-19 found increased blood T-cell numbers in those with severe lymphocytopenia and reduced PD-1 and Tim-3 expression on CD8+ T cells, consistent with reversal of T-cell exhaustion [15], and the ETASS sepsis trial reported improved monocyte HLA-DR expression [17]. Demonstrating that a compound changes an immune marker is a separate matter from demonstrating that it changes an outcome.
What is thymosin alpha 1 used for?
In countries where it is an approved medicine it has been used in chronic viral hepatitis, as an immune-reconstitution agent, and as an adjuvant in oncology; a 2019 reappraisal describes its use in combination with chemotherapy and immunotherapy in melanoma, hepatocellular carcinoma and lung cancer [16]. It has also been studied extensively in sepsis, and that literature is the most instructive part of its record. A 361-patient single-blind trial reported 28-day mortality of 26.0 percent against 35.0 percent in controls, with a nonstratified p-value of 0.062 and a log-rank p-value of 0.049 [17]. A subsequent multicentre, double-blinded, randomised, placebo-controlled phase 3 trial in 1,106 adults found no significant difference — 23.4 percent against 24.1 percent, hazard ratio 0.99, p-value 0.93 [13]. The best-designed test of the sepsis indication was null, and that verdict does not automatically transfer to the indications the trial did not test.
Is thymosin alpha 1 FDA-approved?
No. Thymosin alpha-1 has no United States marketing authorisation, although it is approved as a drug in more than 35 other countries [14]. Some United States orphan-drug designations have existed historically for specific indications; a designation is an incentive status for developing a treatment for a rare disease and is not an approval, and the two are often confused in secondary sources. The Food and Drug Administration has evaluated thymosin alpha-1-related bulk drug substances for pharmacy compounding and has not endorsed them, reflecting unresolved questions about identity, quality and clinical evidence for compounded use. Research-grade material sits outside the regulated drug-quality chain entirely, so purity, content, sterility and identity are unverified.